Archives
I’m working on a new book that I’m super excited about! I’m writing a book on drug interactions and hope to finish by the end of the year! I’m tackling the top 200 drugs plus those I consider very clinically relevant in practice. My hope is that it is a perfect resource for ambulatory care, […]
Read More
In the case scenario below, I discuss the implications of the verapamil phenytoin interaction. JS is a 38-year-old male who has been on phenytoin for seizure prophylaxis for several years. He reports to his primary care provider complaining of severe headaches. He is diagnosed with cluster headaches. Over the next year, he continues to have […]
Read More
In this case scenario below, I discuss the mirabegron tamoxifen interaction and how it can impact patient safety. KS is a 61-year-old female who presents with worsening urinary frequency. She has been diagnosed with overactive bladder and place on oxybutynin. She was taking 5 mg daily and states that the dry mouth from the medication […]
Read More
When the NOACs (sometimes referred to as DOACs) first came out they were heavily promoted as having fewer drug interactions compared to warfarin. This is true, but please remember that “fewer drug interactions” doesn’t mean “no drug interactions”! Here’s a scenario of the carbamazepine apixaban interaction and some potential strategies to manage it. A 72-year-old […]
Read More
Enzyme inducers most frequently reduce the concentrations of other drugs. This can ultimately lead to treatment failure. In rare situations (i.e. prodrugs), starting an enzyme inducer can potentially raise concentrations of the active metabolite and increase the risk for toxicity. Throughout my pharmacy career, I’ve been tested on various enzyme inducers. Here’s my top 5. […]
Read More